A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis

Results in Immunology

Volumn 2, Issue , 2012, Pages 204-211

  Rodriguez, Pedro C ^a   Torres Moya, Roberto ^b   Reyes, Gil ^c   Molinero, Claudino ^b   Prada, Dinorah ^b   Lopez, Ana M ^b   Hernandez, Isabel M ^b   Hernandez, Maria V ^b   Martinez, Jose P ^b   Hernandez, Xochel ^a   Casaco, Angel ^a   Ramos, Mayra ^a   Avila, Yisel ^d   Barrese, Yinet ^d   Montero, Enrique ^a   Hernandez, Patricia ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b National Service for Rheumatology   (Cuba)

^c Rheumatology Service   (Cuba)

^d National Coordinating Centre for Clinical Trials   (Cuba)

Author keywords

CD6; Exploratory study; Rheumatoid arthritis; T lymphocyte

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HEMOGLOBIN; IMMUNOGLOBULIN G ANTIBODY; ITOLIZUMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR;

ADULT; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; ASTHENIA; CHILL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; EXPLORATORY RESEARCH; FEMALE; FEVER; HEADACHE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; JOINT SWELLING; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VOMITING;

EID: 84870282960     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2012.11.001     Document Type: Article

References (60)

1. Sangha O. Epidemiology of rheumatic diseases. Rheumatology 2000, 39(Suppl. 2):3-12.
2. Smith JB, Haynes MK. Rheumatoid arthritis: a molecular understanding. Annals of Internal Medicine 2002, 136:908-922.
3. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology 2003, 42:6-13.
4. Doan T, Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. Journal of Clinical Pharmacology 2005, 45:751-762.
5. Moreland L. Unmet needs in rheumatoid arthritis. Arthritis Research and Therapy 2005, 7:S2-S8.
6. Carter PH, Zhao Q. Clinically validated approaches to the treatment of autoimmune diseases. Expert Opinion on Investigational Drugs 2010, 19:195-213.
7. Panayi GS, Corrigall VM, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheumatic Disease Clinics of North America 2001, 27:317-334.
8. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. New England Journal of Medicine 2001, 344:907-916.
9. Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Current Opinion in Rheumatology 2004, 16:212-217.
10. McInnes I. Leukotrienes, mast cells, and T cells. Arthritis Researchand Therapy 2003, 5:288-289.
11. Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Current Opinion inRheumatology 2000, 12:195-199.
12. Hassan NJ, Barclay AN, Brown MH. Frontline: optimal T cell activation requires the engagement of CD6 and CD166. European Journal of Immunology 2004, 34:930-940.
13. Gimferrer I, Calvo M, Mittelbrunn M, Farnós M, Sarrias MR, Enrich C, et al. Relevance of CD6-mediated interactions in T cell activation and proliferation. Journal ofImmunology 2004, 173:2262-2270.
14. Aruffo A, Melnick MB, Linsley PS, Seed B The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. Journal of Experimental Medicine 1991, 174:949-952.
15. Bodian DL, Skonier JE, Bowen MA, Neubauer M, Siadak AW, Aruffo A, et al. Identification of residues in CD6 which are critical for ligand binding. Biochemistry 1997, 36:2637-2641.
16. Whitney GS, Starling GC, Bowen MA, Modrell B, Siadak AW, Arufo A, et al. The membrane-proximal scavenger receptor cysteinerich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site. Journal of Biological Chemistry 1995, 270:18187-18190.
17. Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN, Figdor CG, et al. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood 2006, 107:3212-3220.
18. Ibanez A, Sarrias MR, Farnos M, Gimferrer I, Serra-Pagès C, Vives J, et al. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. Journal ofImmunology 2006, 177:1152-1159.
19. Singer NG, Fox DA, Haqqi TM, Beretta L, Jsendres, Prohaska S, et al. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. International Immunology 2002, 14:585-597.
20. Nair P, Melarkode R, Rajkumar D, Montero E CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clinicaland Experimental Immunology 2010, 162:116-130.
21. Singer NG, Richardson BC, Powers D, Hooper F, Lialios F, Endres J, et al. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Immunology 1996, 88:537-543.
22. Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology 1986, 36:777-784.
23. Montero E, Falcon L, Morera Y, Delgado J, Amador JF, Perez R CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior T1 MAb a possible new approach to treat this disease. Autoimmunity 1999, 29:155-156.
24. Montero E, Reyes G, Guibert M, Torres O, Rodriguez N, Estrada J, et al. Immunodiagnosis and therapeutic immunosuppression in rheumatoid arthritis with ior t1 (anti-CD6) monoclonal antibody. Arthritis Researchand Therapy 2002, 4(Suppl. 1, Article 38):114.
25. Alonso R, Buors C, Le Dantec C, Hillion S, Pers JO, Saraux A, et al. Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome. Journal of Autoimmunity 2010, 35:336-341.
26. Kirkman RL, Araujo JL, Busch GJ, Carpenter CB, Milford EL, Reinherz EL, et al. Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. Transplantation 1983, 36:620-626.
27. Reinherz EL, Geha R, Rappeport JM, Wilson M, Penta AC, Hussey RE, et al. Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency. Proceedings of the National Academy of Sciences of the United States of America 1982, 79:6047-6051.
28. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics 2009, 41:776-782.
29. Swaminathan B, Matesanz F, Cavanillas ML, Alloza I, Otaegui D, lascoaga JO, et al. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain. Journal ofNeuroimmunology 2010, 223:100-103.
30. Johnson BA, Wang J, Taylor EM, Caillier SJ, Herbert J, Khan OA, et al. Multiple sclerosis susceptibility alleles in African Americans. Genes and Immunity 2010, 11:343-350.
31. Starling GC, Siadak AW, Bowen MA, Aruffo A, Bajorath J, Bodian DL, et al. Bristol-Mayer Squibb Company Monoclonal antibodies to human CD6.6372215.
32. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nature Immunology 2008, 9:137-145.
33. Bott CM, Doshi JB, Morimoto C, Romain PL, Fox DA Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. International Immunology 1993, 5:783-792.
34. Roque-Navarro L, Mateo C, Lombardero J, Mustelier G, Fernández A, Sosa K, et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid and Hybridomics 2003, 22:245-257.
35. Alonso R, Huerta V, de Leon J, Piedra P, Puchades Y, Oguirola, et al. Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. Hybridoma 2008, 27:291-301.
36. Mould DR, Sweeney KR The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Current Opinion in Drug Discoveryand Development 2007, 10:84-96.
37. Waldmann H, Adams E, Cobbold S Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms. Immunological Reviews 2008, 223:361-370.
38. Ibanez A, Sarrias MR, Farnos M, Gimferrer I I, Serra-Pagès C, Vives J, et al. Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. Journal of Immunology 2006, 177:1152-1159.
39. García CA, Gavilondo J, Vázquez AM, Amador JF, Fernandez A A new monoclonal antibody (iort1) that recognize structures in the surface of peripheral blood human T lymphocyte. Proceedings of the IV Scientific Conference on Natural Exact Sciences Biology 1984, vol. 12. p. 395.
40. W Knapp, B Dörken, WR Gilks, EP Rieber, RE Schmidt, H Stein, et al. Leucocyte typing IV. White cell differentiation antigens. Proceedings of the 4th international workshop and conference. Oxford University Press. 1989; p. 517-42.
41. Montero E, Navarro JL, Torres O, Perez M, Sarda L, Vera A, et al. Centro de Ingenieria Genetica y Biotecnologia, editors. Clinical response of Psoriasis Vulgaris patients after scaling-up topical treatment with ior t1 (anti-CD6) monoclonal antibody. In: Proceedings of the 6th International Congress BiotecnologiaHabana 97. Medical Application of Biotechnology. Havana, Cuba. Elfos Scientiae; 1997, p. T36.
42. Montero E, Falcon L, Tormo B, Diaz M, Navarro JL, Perez M, et al. Centro de Ingenieria Genetica y Biotecnologia, editors. Long-lasting remission of psoriatic lesions induced by ior t1 (anti-CD6) monoclonal antibody topical treatment. Proceedings of the 6thInternational Congress Biotecnologia Habana 97. Medical Applications of Biotechnology. Havana, Cuba. Elfos Scientiae; 1997, p. T38.
43. Montero E, Falcon L, Torres O, Morera Y, Urquiza A, Delgado J, et al. Centro de Ingenieria Genetica y Biotecnologia, editors. Comparative effects of ior t1 (anti-CD6) monoclonal antibody and calcipotriol in psoriatic patients. Proceedings of the 6th International Congress Biotecnologia Habana 97. Medical application of Biothecnology. Havana, Cuba. Elfos Scientiae; 1997, p. R10.
44. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, JFFries JF, NSCooper, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritisand Rheumatism 1988, 31:315-324.
45. Syed KM, Pinals RS Leukocytosis in rheumatoid arthritis. Journal of Clinical Rheumatology 1996, 2:197-202.
46. Hamilton P. The haematology laboratory and the rheumatologist. Clin Rheum Dis 1983, 9:69-92.
47. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritisand Rheumatism 2003, 48:2122-2127. BIOBADASER Group.
48. MacKenzie NM. New therapeutics that treat rheumatoid arthritis by blocking T-cell activation. Drug Discovery Today 2006, 11:952-956.
49. Genovese M, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumour necrosis factor a inhibition. New England Journal of Medicine 2005, 353:1114-1123.
50. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Annals of the Rheumatic Diseases 2009, 68:1870-1877.
51. Morimoto C, Rudd CE, Letvin NL, Hagan M, Schlossman SF 2H1-a novel antigen involved in T lymphocyte triggering. Journal ofImmunology 1988, 140:2165-2170.
52. Gangemi RM, Swack JA, Gaviria DM, Romain PL Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes. Journal ofImmunology 1989, 143:2439-2447.
53. Swack JA, Gangemi RM, Rudd CE, Morimoto C, Schlossman SF, Romain PL Structural characterization of CD6: properties of two distinct epitopes involved in T cell activation. Molecular Immunology 1989, 26:1037-1049.
54. Osorio LM, Garcia CA, Jondal M, Chow SC The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation. Cellular Immunology 1994, 154:123-133.
55. Faxas ME, Guerra ME, Avarez A, Calderon C Ensayo clinico fase 1 del anticuerpo monoclonal ior-T1 en linfoma T. Farmacocinetica y respuesta immune. Rev Cubana Med 2003, 42:63-67.
56. Vreugdenhil G, Wognum AW, van Eijk HG, Swaak AJ Anaemia in rheumatoid arthritis: the role of iron, vitamin B12, and folic acid deficiency, and erythropoietin responsiveness. Annals of the Rheumatic Diseases 1990, 49:93-98.
57. Baer AN, Dessypris EN, Krantz SB. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. Seminars in Arthritis and Rheumatism 1990, 19:209-223.
58. Hansen NE. The anaemia of chronic disorders. A bag of unsolved questions. Scandinavian Journal of Haematology 1983, 31:397-402.
59. Minoda M, Horiuchi A. Hematologic abnormalities associated with rheumatoid arthritis. Nippon Rinsho 1992, 50:581-585.
60. Strand V, Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Researchand Therapy 2009, 11:205.